Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07643350 Anlotinib Dihydrochloride Non-small cell lung cancer stage III Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07643350 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126558 CG-001(ComGen) Hemoglobinuria, Paroxysmal Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126558 clinical trial report covering CG-001(ComGen), Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07640932 Lurbinectedin Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07640932 clinical trial report covering Lurbinectedin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07642453 Venetoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07642453 clinical trial report covering Venetoclax, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126555 Toripalimab Renal Pelvis and Ureter Urothelial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126555 clinical trial report covering Toripalimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07642661 Leucovorin Calcium Autism Spectrum Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07642661 clinical trial report covering Leucovorin Calcium, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07640737 AUR103 Gastric Neuroendocrine Tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07640737 clinical trial report covering AUR103, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07643636 Valdecoxib Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07643636 clinical trial report covering Valdecoxib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07643025 Ruxolitinib Chronic graft-versus-host disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07643025 clinical trial report covering Ruxolitinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07641179 MAR002 Acromegaly Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07641179 clinical trial report covering MAR002, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07643428 Fish Oil Triglycerides Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07643428 clinical trial report covering Fish Oil Triglycerides, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07643519 Enfortumab Vedotin-ejfv Renal Pelvis and Ureter Urothelial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07643519 clinical trial report covering Enfortumab Vedotin-ejfv, Phase 2, endpoints, sponsor, geography, readout timing and development white space.